{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:08:03Z","timestamp":1747282083530,"version":"3.40.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Health Science Technology Achievements and Appropriate Technology Promotion Project","award":["No. \u0412\u041d\u0422\u0420\u04202022079"],"award-info":[{"award-number":["No. \u0412\u041d\u0422\u0420\u04202022079"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2021-I2M-1-003"],"award-info":[{"award-number":["CIFMS 2021-I2M-1-003"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-059"],"award-info":[{"award-number":["2022-PUMCH-B-059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00228-025-03837-3","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:05:59Z","timestamp":1744135559000},"page":"863-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of cyclophosphamide for skin fibrosis in systemic sclerosis: a systematic review and single-arm meta-analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Xin","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PengJiao","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RongJi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZaiWei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RongSheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"10373","key":"3837_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V (2023) Systemic sclerosis. Lancet 401(10373):304\u2013318. https:\/\/doi.org\/10.1016\/S0140-6736(22)01692-0","journal-title":"Lancet"},{"issue":"7","key":"3837_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","volume":"15","author":"M Cutolo","year":"2019","unstructured":"Cutolo M, Soldano S, Smith V (2019) Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol 15(7):753\u2013764. https:\/\/doi.org\/10.1080\/1744666X.2019.1614915","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"3837_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44(6):1351\u20131358. https:\/\/doi.org\/10.1002\/1529-0131(200106)44:6%3c1351::AID-ART227%3e3.0.CO;2-I","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3837_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH van den Hoogen","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35(4):364\u2013372. https:\/\/doi.org\/10.1093\/rheumatology\/35.4.364","journal-title":"Br J Rheumatol"},{"issue":"6","key":"3837_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"FA Mendoza","year":"2012","unstructured":"Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39(6):1241\u20131247. https:\/\/doi.org\/10.3899\/jrheum.111229","journal-title":"J Rheumatol"},{"issue":"6","key":"3837_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/ard.2010.142000","volume":"70","author":"EN Le","year":"2011","unstructured":"Le EN, Wigley FM, Shah AA, Boin F, Hummers LK (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70(6):1104\u20131107. https:\/\/doi.org\/10.1136\/ard.2010.142000","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3837_CR7","doi-asserted-by":"publisher","first-page":"CD010908","DOI":"10.1002\/14651858.CD010908.pub2","volume":"1","author":"H Barnes","year":"2018","unstructured":"Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN (2018) Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev 1(1):CD010908. https:\/\/doi.org\/10.1002\/14651858.CD010908.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"3837_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"key":"3837_CR9","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"3837_CR10","first-page":"1892","volume":"20","author":"PJ Clements","year":"1993","unstructured":"Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis (SSc): An assessment of inter-observer variability in three independent studies. J Rheumatol 20:1892\u20131896","journal-title":"J Rheumatol"},{"issue":"2","key":"3837_CR11","first-page":"298","volume":"29","author":"I Pakas","year":"2002","unstructured":"Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29(2):298\u2013304","journal-title":"J Rheumatol"},{"issue":"3","key":"3837_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/acr.23282","volume":"70","author":"R Namas","year":"2018","unstructured":"Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD et al (2018) Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo\u2010controlled trials. Arthritis Care Res (Hoboken) 70(3):439\u2013444. https:\/\/doi.org\/10.1002\/acr.23282","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3837_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","volume":"25","author":"O Nadashkevich","year":"2006","unstructured":"Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25(2):205\u2013212. https:\/\/doi.org\/10.1007\/s10067-005-1157-y","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3837_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/03009740510026896","volume":"35","author":"G Valentini","year":"2006","unstructured":"Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E et al (2006) Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 35(1):35\u201338. https:\/\/doi.org\/10.1080\/03009740510026896","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"3837_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1590\/S0482-50042009000300008","volume":"49","author":"PA de Macedo","year":"2009","unstructured":"de Macedo PA, Borges CTL, de Souza RBC (2009) Cyclophosphamide: Effective in the treatment of severe cutaneous involvement in systemic sclerosis. Rev Bras Reumatol 49(3):265\u2013275","journal-title":"Rev Bras Reumatol"},{"issue":"1","key":"3837_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3899\/jrheum.090668","volume":"37","author":"AL Herrick","year":"2010","unstructured":"Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N et al (2010) Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 37(1):116\u2013124. https:\/\/doi.org\/10.3899\/jrheum.090668","journal-title":"J Rheumatol"},{"issue":"9790","key":"3837_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(11)60982-3","journal-title":"Lancet"},{"issue":"2","key":"3837_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10067-010-1493-4","volume":"30","author":"DS Domiciano","year":"2011","unstructured":"Domiciano DS, Bonf\u00e1 E, Borges CT, Kairalla RA, Capelozzi VL, Parra E et al (2011) A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 30(2):223\u2013229. https:\/\/doi.org\/10.1007\/s10067-010-1493-4","journal-title":"Clin Rheumatol"},{"issue":"8","key":"3837_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00296-010-1398-1","volume":"31","author":"P Ostojic","year":"2011","unstructured":"Ostojic P, Damjanov N (2011) Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis. Rheumatol Int 31(8):1051\u20131054. https:\/\/doi.org\/10.1007\/s00296-010-1398-1","journal-title":"Rheumatol Int"},{"issue":"2","key":"3837_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.reuma.2011.11.006","volume":"8","author":"D P\u00e9rez Campos","year":"2012","unstructured":"P\u00e9rez Campos D, Est\u00e9vez Del Toro M, Pe\u00f1a Casanovas A, Gonz\u00e1lez Rojas PP, Morales S\u00e1nchez L, Guti\u00e9rrez Rojas AR (2012) Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Reumatol Clin 8(2):58\u201362. https:\/\/doi.org\/10.1016\/j.reuma.2011.11.006","journal-title":"Reumatol Clin"},{"issue":"12","key":"3837_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00296-014-3026-y","volume":"34","author":"H Poormoghim","year":"2014","unstructured":"Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S et al (2014) Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement - a retrospective study. Rheumatol Int 34(12):1691\u20131699. https:\/\/doi.org\/10.1007\/s00296-014-3026-y","journal-title":"Rheumatol Int"},{"issue":"24","key":"3837_CR22","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490\u20132498. https:\/\/doi.org\/10.1001\/jama.2014.6368","journal-title":"JAMA"},{"issue":"3","key":"3837_CR23","first-page":"150","volume":"17","author":"A Balbir-Gurman","year":"2015","unstructured":"Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP et al (2015) Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience. Isr Med Assoc J 17(3):150\u2013156","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"3837_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"7","key":"3837_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L et al (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76(7):1207\u20131218. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210503","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3837_CR26","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 57(12):2106\u20132113. https:\/\/doi.org\/10.1093\/rheumatology\/key213","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 125 3","key":"3837_CR27","first-page":"161","volume":"38","author":"C Bruni","year":"2020","unstructured":"Bruni C, Tashkin DP, Steen V, Allanore Y, Distler O, Grotts J et al (2020) Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. Clin Exp Rheumatol 38(Suppl 125 3):161\u2013168","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"3837_CR28","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/rheumatology\/kez487","volume":"59","author":"BE Kersten","year":"2020","unstructured":"Kersten BE, den Broeder N, van den Hoogen FHJ, Knaapen-Hans HAK, van den Ende CHM, Vonk MC (2020) Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. Rheumatology (Oxford) 59(7):1550\u20131555. https:\/\/doi.org\/10.1093\/rheumatology\/kez487","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3837_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/23971983231180077","volume":"8","author":"J Pan","year":"2023","unstructured":"Pan J, Dong F, Ma L, Zhao C, Qin F, Wen J et al (2023) Therapeutic effects of thalidomide on patients with systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord 8(3):231\u2013240. https:\/\/doi.org\/10.1177\/23971983231180077","journal-title":"J Scleroderma Relat Disord"},{"issue":"10","key":"3837_CR30","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.autrev.2016.07.013","volume":"15","author":"A Kuhn","year":"2016","unstructured":"Kuhn A, Landmann A, Bonsmann G (2016) The skin in autoimmune diseases-Unmet needs. Autoimmun Rev 15(10):948\u2013954. https:\/\/doi.org\/10.1016\/j.autrev.2016.07.013","journal-title":"Autoimmun Rev"},{"issue":"11","key":"3837_CR31","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","volume":"43","author":"PJ Clements","year":"2000","unstructured":"Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B et al (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43(11):2445\u20132454. https:\/\/doi.org\/10.1002\/1529-0131(200011)43:11%3c2445::AID-ANR11%3e3.0.CO;2-Q","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3837_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/rheumatology\/kex410","volume":"57","author":"S Peytrignet","year":"2018","unstructured":"Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A et al (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology (Oxford) 57(2):370\u2013381. https:\/\/doi.org\/10.1093\/rheumatology\/kex410","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 5","key":"3837_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/rheumatology\/ken309","volume":"47","author":"L Czirj\u00e1k","year":"2008","unstructured":"Czirj\u00e1k L, Foeldvari I, M\u00fcller-Ladner U (2008) Skin involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):44\u201345. https:\/\/doi.org\/10.1093\/rheumatology\/ken309","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3837_CR34","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/rheumatology\/kez529","volume":"59","author":"T Nevskaya","year":"2020","unstructured":"Nevskaya T, Zheng B, Baxter CA, Ramey DR, Pope JE, Baron M et al (2020) Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology 59(7):1715\u20131724. https:\/\/doi.org\/10.1093\/rheumatology\/kez529","journal-title":"Rheumatology"},{"issue":"2","key":"3837_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/rheumatology\/kez299","volume":"59","author":"B Zheng","year":"2020","unstructured":"Zheng B, Nevskaya T, Baxter CA, Ramey DR, Pope JE, Baron M et al (2020) Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. Rheumatology 59(2):398\u2013406. https:\/\/doi.org\/10.1093\/rheumatology\/kez299","journal-title":"Rheumatology"},{"issue":"6","key":"3837_CR36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/annrheumdis-2012-202849","volume":"73","author":"TR Cottrell","year":"2014","unstructured":"Cottrell TR, Wise RA, Wigley FM, Boin F (2014) The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis 73(6):1060\u20131066. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202849","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3837_CR37","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3899\/jrheum.171443","volume":"45","author":"KW Moon","year":"2018","unstructured":"Moon KW, Lee SS, Lee YJ, Jun JB, Yoo SJ, Ju JH et al (2018) Clinical and laboratory characteristics and mortality in Korean patients with systemic sclerosis: a nationwide multicenter retrospective cohort study. J Rheumatol 45(9):1281\u20131288. https:\/\/doi.org\/10.3899\/jrheum.171443","journal-title":"J Rheumatol"},{"issue":"11","key":"3837_CR38","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group (2018) Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol 70(11):1820\u20131828. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3837_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-024-03418-2","volume":"26","author":"A Wyss","year":"2024","unstructured":"Wyss A, Jordan S, Graf N, Carreira PE, Distler J, Cerinic MM et al (2024) Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis. Arthritis Res Ther 26(1):187. https:\/\/doi.org\/10.1186\/s13075-024-03418-2","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"3837_CR40","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/rheumatology\/keu285","volume":"54","author":"V Nagaraja","year":"2015","unstructured":"Nagaraja V, Denton CP, Khanna D (2015) Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) 54(11):1944\u20131953. https:\/\/doi.org\/10.1093\/rheumatology\/keu285","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"3837_CR41","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1093\/rheumatology\/keab075","volume":"60","author":"RT Domsic","year":"2021","unstructured":"Domsic RT, Gao S, Laffoon M, Wisniewski S, Zhang Y, Steen V et al (2021) Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology (Oxford) 60(10):4662\u20134670. https:\/\/doi.org\/10.1093\/rheumatology\/keab075","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3837_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s10165-010-0403-6","volume":"21","author":"A Tochimoto","year":"2011","unstructured":"Tochimoto A, Kawaguchi Y, Hara M, Tateishi M, Fukasawa C, Takagi K et al (2011) Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol 21(3):296\u2013301. https:\/\/doi.org\/10.1007\/s10165-010-0403-6","journal-title":"Mod Rheumatol"},{"key":"3837_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/1874306400802010039","volume":"2","author":"CP Sime\u00f3n-Aznar","year":"2008","unstructured":"Sime\u00f3n-Aznar CP, Fonollosa-Pl\u00e1 V, Tolosa-Vilella C, Selva-O Callaghan A, Solans-Laqu\u00e9 R, Palliza E et al (2008) Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2:39\u201345. https:\/\/doi.org\/10.2174\/1874306400802010039","journal-title":"Open Respir Med J"},{"issue":"10","key":"3837_CR44","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","volume":"176","author":"DP Tashkin","year":"2007","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176(10):1026\u20131034. https:\/\/doi.org\/10.1164\/rccm.200702-326OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3837_CR45","doi-asserted-by":"publisher","first-page":"CD011819","DOI":"10.1002\/14651858.CD011819.pub2","volume":"7","author":"S Bruera","year":"2022","unstructured":"Bruera S, Sidanmat H, Molony DA, Mayes MD, Suarez-Almazor ME, Krause K et al (2022) Stem cell transplantation for systemic sclerosis. Cochrane Database Syst Rev 7(7):CD011819. https:\/\/doi.org\/10.1002\/14651858.CD011819.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3837_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40674-016-0040-0","volume":"2","author":"S Kafaja","year":"2016","unstructured":"Kafaja S, Clements P (2016) Management of widespread skin thickening in diffuse systemic sclerosis. Curr Treatm Opt Rheumatol 2(1):49\u201360. https:\/\/doi.org\/10.1007\/s40674-016-0040-0","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"3837_CR47","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1056\/NEJMe068095","volume":"354","author":"FJ Martinez","year":"2006","unstructured":"Martinez FJ, McCune WJ (2006) Cyclophosphamide for scleroderma lung disease [editorial]. N Engl J Med 354:2707\u20132709","journal-title":"N Engl J Med"},{"key":"3837_CR48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","volume":"124","author":"C Talar-Williams","year":"1996","unstructured":"Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I et al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477\u2013484. https:\/\/doi.org\/10.7326\/0003-4819-124-5-199603010-00003","journal-title":"Ann Intern Med"},{"issue":"1","key":"3837_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.25061","volume":"62","author":"PA Monach","year":"2010","unstructured":"Monach PA, Arnold LM, Merkel PA (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 62(1):9\u201321. https:\/\/doi.org\/10.1002\/art.25061","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3837_CR50","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1164\/rccm.200708-1185ED","volume":"176","author":"AU Wells","year":"2007","unstructured":"Wells AU, Latsi P, McCune WJ (2007) Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial? Am J Respir Crit Care Med 176(10):952\u2013953. https:\/\/doi.org\/10.1164\/rccm.200708-1185ED","journal-title":"Am J Respir Crit Care Med"},{"key":"3837_CR51","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"issue":"SI","key":"3837_CR52","doi-asserted-by":"publisher","first-page":"SI54","DOI":"10.1093\/rheumatology\/keac363","volume":"62","author":"M Hughes","year":"2023","unstructured":"Hughes M, Huang S, Alegre-Sancho JJ, Carreira PE, Engelhart M, Hachulla E et al (2023) Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford) 62(SI):SI54\u2013SI63. https:\/\/doi.org\/10.1093\/rheumatology\/keac363","journal-title":"Rheumatology (Oxford)"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03837-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03837-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03837-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:59:16Z","timestamp":1747205956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03837-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3837"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03837-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}